Home
Clinical Trials
S0622, Dasatinib in Treating ...

S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone

Last Updated: 2017-07-02

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

85 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-03-31

Study Completion Date

2014-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This randomized phase II trial is studying two different schedules of dasatinib to compare how well they work in treating patients with stage IV breast cancer that has spread to the bone.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

NCT00566618

Breast Cancer Bone Metastases

COMPLETED PHASE1/PHASE2

Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer

NCT00452673

Advanced Breast Cancer

COMPLETED PHASE1

Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194

NCT00820170

Breast Cancer

COMPLETED PHASE1/PHASE2

Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer

NCT00096109

Recurrent Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer +1 more

TERMINATED PHASE2

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

NCT01281163

Estrogen Receptor Negative Estrogen Receptor Positive HER2/Neu Positive +4 more

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Compare the progression-free survival of patients with stage IV bone metastasis-predominant breast cancer treated with 1 of 2 treatment schedules of dasatinib.
* Compare the response rate (complete and partial, confirmed and unconfirmed) in patients treated with these regimens.
* Compare the MUC-1 antigen response rate (CA 15-3 or CA 27-29) in patients treated with these regimens.
* Compare the circulating tumor cell response rate in patients treated with these regimens.
* Compare the anti-osteoclast activity, as measured by changes in bone turnover markers, in patients treated with these regimens.
* Compare the frequency and severity of toxicities of these regimens in these patients.
* Compare the pain profiles of these patients and explore changes over time.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to concurrent trastuzumab (Herceptin®) treatment (yes vs no). Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients receive oral dasatinib once daily.
* Arm II: Patients receive oral dasatinib twice daily. In both treatment arms, treatment continues for at least 24 weeks in the absence of disease progression or unacceptable toxicity.

Blood samples are acquired from patients once weekly in weeks 1, 4, 8, 16, and 24. Samples are analyzed for tumor markers, circulating tumor cells, and bone markers.

Patients complete a self-reported brief pain inventory questionnaire at baseline and once in weeks 8, 16, and 24.

After completion of study treatment, patients are followed every 3-6 months for up to 2 years.

PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Metastatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I

Patients receive oral dasatinib once daily.

Group Type EXPERIMENTAL

dasatinib

Intervention Type DRUG

given orally

Arm II

Patients receive oral dasatinib twice daily.

Group Type EXPERIMENTAL

dasatinib

Intervention Type DRUG

given orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

dasatinib

given orally

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Diagnosis of breast carcinoma meeting the following criteria:

* Stage IV disease
* Bone metastasis-predominant disease, defined as the presence of ≥ 1 bone metastasis with or without nonbone (visceral or soft tissue) disease where the number of bone metastases is at least the number of measurable visceral target lesions

* Visceral disease that does not cause a reduction in ECOG performance status allowed
* Must meet 1 of the following criteria:

* Measurable disease within the past 28 days
* Nonmeasurable disease with rising serum CA 15-3, CA 27-29, CEA, or CA-125 documented by 2 consecutive measurements taken ≥ 14 days apart with the most recent measurement being within the past 42 days

* These measurements need not be consecutive, and the prior measurement could have been months to years prior to the current measurement if the marker is considered by the investigator to reflect disease progression
* The second serum marker value must be greater than the institution's upper limit of normal and show ≥ a 20% increase over the first measurement
* No symptomatic brain or CNS metastases

* Prior CNS or brain metastasis allowed provided it was treated with radiotherapy ≥ 8 weeks ago
* No pleural or pericardial effusion
* Hormone receptor status known

* Estrogen receptor- and/or progesterone receptor-positive disease must have progressed on ≥ 1 hormonal therapy in the metastatic setting

PATIENT CHARACTERISTICS:

* Male or female
* Menopausal status not specified
* Zubrod performance status 0-2
* QTc \< 450 msec by EKG
* Ejection fraction ≥ 50% by MUGA or 2-dimensional echocardiogram with no significant abnormalities within the past 12 weeks for patients on trastuzumab
* No active infection requiring systemic therapy
* No uncontrolled concurrent condition that would preclude the ability to take oral medication, including the following:

* Nausea
* Vomiting
* Diarrhea
* Lack of physical integrity of the upper gastrointestinal tract
* Malabsorption syndrome
* No clinically significant cardiac disease, including the following:

* Congestive heart failure
* Symptomatic coronary artery disease
* Cardiac arrhythmias not well controlled
* Myocardial infarction within the past 12 months
* No concurrent active malignancy

* Prior malignancies allowed provided the patient is currently disease-free
* Not pregnant or nursing
* Fertile patients must use effective contraception during and for 3 months after completion of study therapy

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No prior RankL inhibitor therapy
* No more than 1 prior cytotoxic chemotherapy for metastatic disease
* At least 3 weeks since prior chemotherapy and recovered
* At least 1 week since prior radiotherapy to non-CNS disease and recovered
* At least 3 weeks since prior and no concurrent intravenous bisphosphates (e.g., zoledronate)
* At least 7 days since prior and no concurrent antiplatelet agents, including any of the following\*:

* Anticoagulants (e.g., tirofiban, eptifibatide, ticlopidine)
* Aspirin or aspirin-containing combinations
* Dipyridamole
* Epoprostenol
* Clopidogrel
* Cilostazol
* Abciximab NOTE: \*Nonsteroidal anti-inflammatory drugs and medically indicated platelet-inhibiting medication allowed
* At least 7 days since prior and no concurrent CYP3A4 inhibitors, including any of the following:

* HIV protease inhibitors (e.g., amprenavir, atazanavir, fosamprenavir, indinavir, nelfinavir, ritonavir)
* Select antibiotics (e.g., ciprofloxacin, clarithromycin, doxycycline, enoxacin, isoniazid, telithromycin)
* Azole antifungals (e.g., itraconazole, ketoconazole, miconazole, voriconazole)
* Select anesthetics (e.g., ketamine, propofol)
* Hypericum perforatum (St. John's wort)
* Nefazodone
* Nicardipine
* Diclofenac
* Quinidine
* Imatinib mesylate
* At least 7 days since prior and no concurrent medications that prolong the QTc interval, including any of the following:

* Antiarrhythmic agents (e.g., quinidine, procainamide, disopyramide phosphate, amiodarone, sotalol hydrochloride, ibutilide, dofetilide)
* Antipsychotic agents (e.g., chlorpromazine, mesoridazine, thioridazine, pimozide, haloperidol, droperidol)
* Select antibiotics (e.g., erythromycin, clarithromycin, sparfloxacin, pentamidine)
* Narcotic analgesics (e.g., levomethadyl, methadone, domperidone)
* Calcium channel blockers (e.g., bepridil, lidoflazine)
* Antimalarial agents (e.g., halofantrine, chloroquine)
* Parasympathomimetic agents (e.g., cisapride)
* Arsenic trioxide
* No other concurrent antineoplastic therapy for breast cancer, including any of the following:

* Radiotherapy
* Chemotherapy
* Immunotherapy
* Biologic therapy
* Hormonal therapy
* Gene therapy
* No concurrent grapefruit juice consumption
* No concurrent short-acting antacid agents within 2 hours of dasatinib administration
* Concurrent trastuzumab (Herceptin®) therapy for HER-2 positive patients allowed provided patients have been on continuous trastuzumab for ≥ 12 weeks

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anne F. Schott, MD

Role: STUDY_CHAIR

University of Michigan Rogel Cancer Center

Catherine Van Poznak, MD

Role: STUDY_CHAIR

University of Michigan Rogel Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Providence Cancer Center at Providence Hospital

Mobile, Alabama, United States

Site Status

Alaska Regional Hospital Cancer Center

Anchorage, Alaska, United States

Site Status

Providence Cancer Center

Anchorage, Alaska, United States

Site Status

Highlands Oncology Group - Springdale

Bentonville, Arkansas, United States

Site Status

Arkansas Cancer Research Center at University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Site Status

East Bay Radiation Oncology Center

Castro Valley, California, United States

Site Status

Eden Medical Center

Castro Valley, California, United States

Site Status

Valley Medical Oncology Consultants - Castro Valley

Castro Valley, California, United States

Site Status

Valley Medical Oncology

Fremont, California, United States

Site Status

Contra Costa Regional Medical Center

Martinez, California, United States

Site Status

Tibotec Therapeutics - Division of Ortho Biotech Products, LP

Marysville, California, United States

Site Status